Clinical Characteristics, Antimicrobial Susceptibility, and Outcomes of Streptococcus suis Infection: A Case Series from Southern Thailand
Abstract
Objective: To describe the clinical characteristics, antimicrobial susceptibility profiles, and outcomes of patients with Streptococcus suis infection in Southern Thailand.
Methods: We conducted a retrospective case series of patients with microbiologically confirmed S. suis infection at Songklanagarind Hospital, a tertiary-care hospital in Southern Thailand, between 2019 and 2025. Clinical data were extracted from electronic medical records. Antimicrobial susceptibility testing was performed using automated minimum inhibitory concentration (MIC) methods and interpreted according to CLSI M100 criteria for viridans group streptococci.
Results: Sixteen cases were identified (median age 64.5 years [IQR 51.5–70.3]; 56.3% male). A potential zoonotic exposure (pig contact or raw pork consumption) was identified in 4 of 16 patients (25.0%). Bacteremia was the most frequent finding (75.0%); infective endocarditis was the most common focal manifestation (50.0%), followed by spondylodiscitis (25.0%). Ceftriaxone was the most frequently used definitive therapy (68.8%), with a median intravenous treatment duration of 42 days. Among 13 isolates tested, all were susceptible to ceftriaxone, and no penicillin-resistant isolates were detected, although 30.8% showed intermediate susceptibility. Resistance to erythromycin and tetracycline was universal. In-hospital mortality was 18.8%.
Conclusion: In this single-center series, S. suis infection in Southern Thailand frequently presented with infective endocarditis, while isolates retained susceptibility to beta-lactams. Ceftriaxone appeared to be a reliable treatment option, whereas resistance to macrolides and tetracyclines was widespread. These findings provide regional data that may help inform clinical management, although larger prospective studies are needed.
Keywords
Full Text:
PDF (Early Version)References
Feng Y, Zhang H, Wu Z, Wang S, Cao M, Hu D, et al. Streptococcus suis infection. Virulence. 2014 May 15;5(4):477–97.
Gajdács M, Németh A, Knausz M, Barrak I, Stájer A, Mestyán G, et al. Streptococcus suis: An Underestimated Emerging Pathogen in Hungary? Microorganisms. 2020 Sep;8(9):1292.
Panpaeng C, Kamolvit W, Karaketklang K, Jitmuang A. Clinical characteristics and trends in the antimicrobial susceptibility profile of Streptococcus suis infections in a large tertiary hospital, Thailand, 2007-2023. PLoS Negl Trop Dis. 2025 May;19(5):e0013110.
Wangsomboonsiri W, Luksananun T, Saksornchai S, Ketwong K, Sungkanuparph S. Streptococcus suis infection and risk factors for mortality. J Infect. 2008 Nov;57(5):392–6.
Wangkaew S, Chaiwarith R, Tharavichitkul P, Supparatpinyo K. Streptococcus suis infection: a series of 41 cases from Chiang Mai University Hospital. J Infect. 2006 Jun;52(6):455–60.
Rayanakorn A, Katip W, Goh BH, Oberdorfer P, Lee LH. Clinical Manifestations and Risk Factors of Streptococcus suis Mortality Among Northern Thai Population: Retrospective 13-Year Cohort Study. Infect Drug Resist. 2019;12:3955–65.
MEEKHANON N, KAEWMONGKOL S, JIRAWATTANAPONG P, KAMINSONSAKUL T, KONGSOI S, CHUMSING S, et al. High rate misidentification of biochemically determined Streptococcus isolates from swine clinical specimens. J Vet Med Sci. 2019 Apr;81(4):567–72.
Huong VTL, Ha N, Huy NT, Horby P, Nghia HDT, Thiem VD, et al. Epidemiology, clinical manifestations, and outcomes of Streptococcus suis infection in humans. Emerg Infect Dis. 2014 Jul;20(7):1105–14.
Goyette-Desjardins G, Auger JP, Xu J, Segura M, Gottschalk M. Streptococcus suis, an important pig pathogen and emerging zoonotic agent—an update on the worldwide distribution based on serotyping and sequence typing. Emerging Microbes & Infections. 2014 Jun 18;3(6):e45.
Lun ZR, Wang QP, Chen XG, Li AX, Zhu XQ. Streptococcus suis: an emerging zoonotic pathogen. Lancet Infect Dis. 2007 Mar;7(3):201–9.
Kerdsin A. Human Streptococcus suis Infections in Thailand: Epidemiology, Clinical Features, Genotypes, and Susceptibility. Trop Med Infect Dis. 2022 Nov 8;7(11):359.
Takeuchi D, Kerdsin A, Pienpringam A, Loetthong P, Samerchea S, Luangsuk P, et al. Population-based study of Streptococcus suis infection in humans in Phayao Province in northern Thailand. PLoS One. 2012;7(2):e31265.
Praphasiri P, Owusu JT, Thammathitiwat S, Ditsungnoen D, Boonmongkon P, Sangwichian O, et al. Streptococcus suis Infection in Hospitalized Patients, Nakhon Phanom Province, Thailand. Emerg Infect Dis. 2015 Feb;21(2):345–8.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing 35th ed. M100. 35th ed. Wayne, PA: CLSI; 2025.
Thipmontree W, Lerssuttipon U, Chunharas P, Kajeekul R, Lewrod A, Yongkiettrakul S, et al. Streptococcus suis endocarditis: prognostic factors and antimicrobial resistance. Infection. 2025 Oct;53(5):1779–87.
Kajeekul R, Brizuela J, Ruenroengbun N, Schultsz C, Kerdsin A. Novel zoonotic Streptococcus suis lineage causes infective endocarditis with high mortality in Thailand. Eur J Clin Microbiol Infect Dis. 2025 Nov;44(11):2717–24.
Rayanakorn A, Goh BH, Lee LH, Khan TM, Saokaew S. Risk factors for Streptococcus suis infection: A systematic review and meta-analysis. Sci Rep. 2018 Sep 6;8(1):13358.
Lv R, Zhang W, Sun Z, Si X, Dong H, Liu X. Current prevalence and therapeutic strategies for porcine Streptococcus suis in China. Applied and Environmental Microbiology. 2025 Feb 25;91(3):e02160-24.
Rayanakorn A, Katip W, Ademi Z, Chan KG. Treatment costs for patients with Streptococcus suis infection in Northern Thailand: a hospital-based observational study of 14-year data. BMC Public Health. 2023 Apr 21;23(1):737.
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.